Sfoglia per Soggetto "Antineoplastic Agents"
Items 21-27 di 27
-
Recent Advances on the Anticancer Properties of Saffron (Crocus sativus L.) and Its Major Constituents
(2021)Cancer is the second leading cause of death globally with an estimated 9.6 million deaths in 2018 and a sustained rise in its incidence in both developing and developed countries. According to the WHO, about 1 in 6 deaths ... -
The role of histone deacetylase inhibitors in uveal melanoma: Current evidence
(2018)Uveal melanoma is the most common intraocular malignancy in adults, representing approximately 3% of all melanoma cases. Despite progress in chemotherapy, radiation and surgical treatment options, the prognosis and survival ... -
Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine to Treat Pancreatic Cancer
(2018)A novel, multifunctional hydrogel that exhibits a unique set of properties for the effective treatment of pancreatic cancer (PC) is presented. The material is composed of a pentablock terpolypeptide of the type ... -
Sexual dysfunction in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection: A focus beyond ejaculation disorders
(2016)Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) represents an integral part of multidisciplinary treatment of advanced germ cell cancer; however, it is associated with a high complications rate. The ... -
Tumor chemosensitivity assays are helpful for personalized Cytotoxic treatments in cancer patients
(2021)Tumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations ... -
Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG)
(2016)Purpose: Following the establishment of adjuvant carboplatin in stage I testicular seminoma as a standard, we adopted this treatment for all stage I seminoma patients. We report our 8-year experience and compare these ... -
What may constrain the success of indoleamine 2,3-dioxygenase 1 inhibitors in cancer immunotherapy?
(2018)[No abstract available]